

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

Toledo

RRID:CVCL_3611

Type: Cell Line

Proper Citation

RRID:CVCL_3611

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3611

Proper Citation: RRID:CVCL_3611

Description: Cell line Toledo is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:10485273](#), [PMID:19278952](#), [PMID:19358282](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:23292937](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30165192](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Toledo

Synonyms: TOLEDO

Cross References: CLO:CLO_0009382, EFO:EFO_0002383, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-2631, BCRC:60544, BCRJ:0235, BioSample:SAMN03472953, BioSample:SAMN10987633, cancercellines:CVCL_3611, Cell_Model_Passport:SIDM01758, ChEMBL-Cells:ChEMBL4295464, ChEMBL-Targets:ChEMBL4296505, Cosmic:1541917, Cosmic:1670183, Cosmic:1945195, Cosmic:2022502, Cosmic:2276337, DepMap:ACH-

000285, EGA:EGAS00001000610, GDSC:1331046, GEO:GSM380151, GEO:GSM552462, GEO:GSM887709, GEO:GSM888802, GEO:GSM907526, GEO:GSM1035336, GEO:GSM3150257, IARC_TP53:28341, IGRhCellID:Toledo, LiGeA:CCLE_102, LINCS_LDP:LCL-1124, PharmacDB:Toledo_1603_2019, PRIDE:PXD012087, Progenetix:CVCL_3611, PubChem_Cell_line:CVCL_3611, Wikidata:Q54972777

ID: CVCL_3611

Record Creation Time: 20220427T221632+0000

Record Last Update: 20260905T182559+0000

Ratings and Alerts

No rating or validation information has been found for Toledo.

No alerts have been found for Toledo.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. Research square.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. Molecular cell, 85(13), 2597.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Priam P, et al. (2024) Smarcd1 subunit of SWI/SNF chromatin-remodeling complexes collaborates with E2a to promote murine lymphoid specification. Developmental cell, 59(23), 3124.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. *Science advances*, 8(39), eabq0117.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. *Cell reports*, 31(13), 107840.

Park S, et al. (2020) Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. *Cancers*, 12(9).

Zhang J, et al. (2020) Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. *Cell chemical biology*, 27(12), 1500.

Carr M, et al. (2020) IKK γ and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKK γ /TBK1 inhibitor to repress NF- κ B and IL-10 signalling. *Journal of cellular and molecular medicine*, 24(19), 11573.

Guièze R, et al. (2019) Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. *Cancer cell*, 36(4), 369.

Yamagishi M, et al. (2019) Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. *Cell reports*, 29(8), 2321.

Li M, et al. (2019) Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. *Cancer cell*, 35(6), 916.